Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Completed 5Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Plasma cell 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Multiple Myeloma 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × L-BLP25 × Thoracic × Clear all
NCT02049151 2017-08-23

START2

EMD Serono

Phase 3 Terminated
35 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01015443 2016-10-26

INSPIRE

Merck KGaA, Darmstadt, Germany

Phase 3 Terminated
285 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡